Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy

[1]  Jean-Michel Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.

[2]  Guangdi Li,et al.  Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time , 2016, Reviews in medical virology.

[3]  F. Ceccherini‐Silberstein,et al.  From current status to optimization of HCV treatment: Recommendations from an expert panel. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[4]  M. Soares,et al.  In-depth phylogenetic analysis of hepatitis C virus subtype 1a and occurrence of 80K and associated polymorphisms in the NS3 protease , 2016, Scientific Reports.

[5]  Kristof Theys,et al.  Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development , 2016, Virus evolution.

[6]  Andrea D. Olmstead,et al.  Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada. , 2016, Journal of hepatology.

[7]  M. Suchard,et al.  SpreaD3: Interactive Visualization of Spatiotemporal History and Trait Evolutionary Processes. , 2016, Molecular biology and evolution.

[8]  T. C. Chang,et al.  A cluster of Mycobacterium massiliense keratitis in foundry workers. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  A. Lazzarin,et al.  Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  E. Yoshida,et al.  Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2) , 2016, Hepatology.

[11]  Andrew Rambaut,et al.  Exploring the temporal structure of heterochronous sequences using TempEst (formerly Path-O-Gen) , 2016, Virus evolution.

[12]  G. Filice,et al.  Safety and Efficacy of Directly Acting Antivirals in 2432 HCV Patients with Advanced Fibrosis: An Interim Analysis of the Lombardia Regional Network for Viral Hepatitis , 2016 .

[13]  M. Manns,et al.  Treatment Outcomes for Hepatitis C Genotype 1 Infection with Direct Acting Antivirals: Data from the German Hepatitis C-Registry , 2016 .

[14]  Andrew J. Tatem,et al.  Virus evolution and transmission in an ever more connected world , 2015, Proceedings of the Royal Society B: Biological Sciences.

[15]  K. Childs,et al.  Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK. , 2015, Clinical Microbiology and Infection.

[16]  Pieter J. K. Libin,et al.  Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1–6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance , 2015, Viruses.

[17]  Richard H. Liang,et al.  Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism. , 2015, The Journal of infectious diseases.

[18]  C. Sarrazin,et al.  Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. , 2015, Antiviral research.

[19]  R. Kaiser,et al.  Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors , 2015, Open forum infectious diseases.

[20]  Monika Henzinger,et al.  Split diversity in constrained conservation prioritization using integer linear programming , 2014, Methods in ecology and evolution.

[21]  H. Razavi,et al.  Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.

[22]  Glenn Lawyer,et al.  COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification , 2014, Nucleic acids research.

[23]  C. Sarrazin,et al.  Antiviral therapy of hepatitis C in 2014: do we need resistance testing? , 2014, Antiviral research.

[24]  Michael Worobey,et al.  A synchronized global sweep of the internal genes of modern avian influenza virus , 2014, Nature.

[25]  Guy Baele,et al.  The Genealogical Population Dynamics of HIV-1 in a Large Transmission Chain: Bridging within and among Host Evolutionary Rates , 2014, PLoS Comput. Biol..

[26]  F. Baldanti,et al.  Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients , 2012, Virology Journal.

[27]  Stefano Alcaro,et al.  HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors , 2012, PloS one.

[28]  M. Suchard,et al.  Bayesian Phylogenetics with BEAUti and the BEAST 1.7 , 2012, Molecular biology and evolution.

[29]  M. Bracho,et al.  Recombination in Hepatitis C Virus , 2011, Viruses.

[30]  R. Striker,et al.  Evidence for separation of HCV subtype 1a into two distinct clades , 2011, Journal of viral hepatitis.

[31]  John J. Welch,et al.  Ancient Hybridization and an Irish Origin for the Modern Polar Bear Matriline , 2011, Current Biology.

[32]  Rebecca R. Gray,et al.  The mode and tempo of hepatitis C virus evolution within and among hosts , 2011, BMC Evolutionary Biology.

[33]  M. Suchard,et al.  Bayesian random local clocks, or one rate to rule them all , 2010, BMC Biology.

[34]  O. Pybus,et al.  The Global Spread of Hepatitis C Virus 1a and 1b: A Phylodynamic and Phylogeographic Analysis , 2009, PLoS medicine.

[35]  Alexei J. Drummond,et al.  Bayesian Phylogeography Finds Its Roots , 2009, PLoS Comput. Biol..

[36]  Marc A. Suchard,et al.  Many-core algorithms for statistical phylogenetics , 2009, Bioinform..

[37]  Marc A Suchard,et al.  Counting labeled transitions in continuous-time Markov models of evolution , 2007, Journal of mathematical biology.

[38]  Tony O’Hagan.  Bayes factors , 2006 .

[39]  S. Ho,et al.  Relaxed Phylogenetics and Dating with Confidence , 2006, PLoS biology.

[40]  T. Geisel,et al.  The scaling laws of human travel , 2006, Nature.

[41]  Tulio de Oliveira,et al.  An automated genotyping system for analysis of HIV-1 and other microbial sequences , 2005, Bioinform..

[42]  O. Pybus,et al.  Viral gene sequences reveal the variable history of hepatitis C virus infection among countries. , 2004, The Journal of infectious diseases.

[43]  T. Gojobori,et al.  A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[44]  P. Simmonds,et al.  A genetic analysis of hepatitis C virus transmission between injection drug users. , 2002, The Journal of infectious diseases.

[45]  Dennis Wepman.  Immigration : from the founding of Virginia to the closing of Ellis Island , 2002 .

[46]  O. Pybus,et al.  The Epidemic Behavior of the Hepatitis C Virus , 2001, Science.

[47]  Z. Yang,et al.  Estimation of primate speciation dates using local molecular clocks. , 2000, Molecular biology and evolution.

[48]  C. Tinelli,et al.  Molecular epidemiology of hepatitis C virus infection among intravenous drug users. , 1995, Journal of hepatology.

[49]  J. Felsenstein.  Cases in which Parsimony or Compatibility Methods will be Positively Misleading , 1978 .

[50]  G. Monticelli.  Italian Emigration: Basic Characteristic and Trends with Special Reference to the Last Twenty Years , 1967, The International Migration Digest.

[51]  Elizabeth Cometti.  Trends in Italian Emigration , 1958 .